SK Bioscience joins US-backed project to develop Bundibugyo Ebola vaccine

A monumental Ebola outbreak is currently plaguing the Democratic Republic of Congo, with over 10,000 confirmed cases as of Tuesday, according to government data. This rapidly spreading outbreak is the most extensive and deadly to date in the country's history, claiming nearly half of its 10,060 confirmed cases. Caused by the rare Bundibugyo virus, with no approved vaccine or treatment, the outbreak has been further complicated by armed conflict, poor infrastructure, and widespread mistrust and misinformation.

Multiple African nations, including Uganda and France, have reported cases, the first being recorded in Kenya and Nigeria. The outbreak has spread to 66 health zones across eight provinces, from a mere three zones at its inception in May. While at least 2,600 patients have recovered, emphasizing moments of relief, the virus remains a formidable threat.

With 80% of new cases occurring outside monitored contacts, health authorities are grappling with unrecognized chains of transmission. Despite the extensive impact on essential healthcare services, which are already strained, the World Health Organization's Tedros Adhanom Ghebreyesus emphasized that "every life saved is worth celebrating," as the crisis persists.